Shop by goal

  • Metabolic Research
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories
  • All compounds →

    • Popular compounds

  • BPC-157
  • TB-500
  • GHK-Cu
  • GLP1-RC-RT
  • GLP1-RC-SM
  • Ipamorelin
  • All bestsellers →

    • Research resources

  • Research Glossary
  • Peptide Guides
  • Delivery Guide
  • Track Order

    • Recently viewed

  • Peptide 101
  • Research Areas
  • Peptide Blog
  • Community Forum
  • Crypto Blog
  • Research Glossary
  • Reconstitution Calculator
  • Peptide Tracker
  • Research Protocol Tools
  • Peptide Guides
  • Sign In
  • Create Account
  • Track My Order
  • Refer a Friend
  • My Account
  • My Orders
  • My Referrals
  • Log Out
    • How-to guides

    Research comparison

    Liraglutide vs Semaglutide

    Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

    Updated August 2026 Research use only

    LIRAGLUTIDE

    Liraglutide

    GLP-1

    GLP-1R

    GLP1-RC-SM

    Semaglutide

    GLP-1R agonist

    GLP-1R

    Key research differences

    Liraglutide Semaglutide Receptor profile GLP-1R GLP-1R Development status Approved therapeutic molecule Approved therapeutic molecule Published half-life 13 h ~6.9 days (165 h) Research distinction Shorter-acting GLP-1R agonism Selective GLP-1R agonism

    Published research parameters

    Liraglutide Saxenda, Victoza Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Receptor profile GLP-1R GLP-1R Class GLP-1 GLP-1R agonist Plasma half-life 13 h ~6.9 days (165 h) Time to Cmax 11 h 24 h Development status Approved therapeutic molecule Approved therapeutic molecule Study context Regulatory label PK Regulatory label PK Primary publications FDA Saxenda USPI — half-life ~13 h (2023) FDA Wegovy USPI — half-life ~1 week (165 h) (2024) Summary Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects. View published study parameters Liraglutide Saxenda, Victoza Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Route in published studies Subcutaneous Subcutaneous Published study interval Once daily Once weekly Published dose range 0.6–3 mg 0.25–2.4 mg Published study regimen 0.6 → 1.2 → 1.8 → 2.4 → 3 mg 0.25 → 0.5 → 1 → 1.7 → 2.4 mg

    Source references

    FDA Saxenda USPI — half-life ~13 h

    FDA prescribing information · 2023

    FDA Saxenda USPI — half-life ~13 h (2023)

    Pi-Sunyer X et al.

    New England Journal of Medicine · 2015

    Pi-Sunyer X et al., NEJM 373:11 (2015)

    FDA Wegovy USPI — half-life ~1 week (165 h)

    FDA prescribing information · 2024

    FDA Wegovy USPI — half-life ~1 week (165 h) (2024)

    STEP 1 trial — NEJM 384:989 (titration schedule)

    New England Journal of Medicine · 2021

    STEP 1 trial — NEJM 384:989 (titration schedule) (2021)

    Hall S et al.

    Clinical Pharmacokinetics · 2018

    Hall S et al., Clin Pharmacokinet 57:1571 (Cmax ~24 h SC) (2018)

    Frequently asked questions

    What is the difference between Liraglutide and Semaglutide? Which has a longer half-life, Liraglutide or Semaglutide? How often is each compound dosed in the research literature? Can you buy Liraglutide and Semaglutide for research use?

    Continue researching

    Research guides, current certificates and related research for Liraglutide and Semaglutide. Research use only.

  • Research guide Semaglutide research guide Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a… Read the guide →
  • Analytical evidence View the Semaglutide COA Current batch purity and identity testing, 2025-04-30. View the COA →
  • Related research Retatrutide vs semaglutide: triple agonist vs GLP-1, compared Triple (GIP/GLP-1/glucagon) vs single GLP-1 agonism, the Phase 2/3 weight-loss data (24.2% vs 14.9%), regulatory status and side effects… Read the article →
  • Compare Compare Semaglutide and Retatrutide Semaglutide vs Retatrutide: mechanism, receptor profile and specifications side by side. Compare →

    • Continue research

    ← Compare other compounds

    PRECISION. PURITY. PERFORMANCE.

    Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

    Shop

  • All research compounds
  • Price list
  • Where to buy peptides
  • Compare compounds
  • Compare vial sizes
  • Affiliate programme

    • Research

  • Peptide 101
  • Published COAs
  • Research areas
  • Research blog
  • How-to guides
  • Peptide guides
  • Research glossary

    • Support

  • Track your order
  • Contact us
  • Shipping & delivery
  • International shipping
  • FAQ
  • Community forum
  • Refund policy

    • Ways to Pay

  • Google Pay
  • Apple Pay
  • Venmo
  • Cryptocurrency
  • Crypto wallets
  • Cash App
  • Card payments
  • Bank transfer (SEPA)
  • Paying with crypto
  • Live crypto prices

    • Shop by goal

  • Metabolic Research
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories

    • Shop by compound

  • BPC-157
  • TB-500
  • GHK-Cu
  • Tesamorelin
  • Retatrutide
  • Semaglutide
  • Tirzepatide
  • CJC-1295 (without DAC)
  • All compounds →

    • Shop by region

  • United Kingdom
  • United States
  • Australia
  • Canada
  • Canada (FR)
  • Ireland
  • Northern Ireland
  • Malta
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Portugal
  • Greece
  • Austria
  • Poland
  • Sweden
  • Finland
  • Denmark
  • Norway
  • Croatia
  • Slovakia
  • Slovenia
  • Estonia
  • Latvia
  • Lithuania
  • Czechia
  • Hungary
  • Romania
  • Bulgaria
  • Belgium
  • Belgium (FR)
  • Luxembourg
  • Deutsch
  • Ελληνικά
  • Español
  • Français
  • Italiano

    • Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.

    All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

    Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

    Principal office: 1712 Pioneer Ave., Ste. 500, Cheyenne, WY 82001, USA

    © 2026 New-U Research Compounds · new-u.io

    Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.